The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Genetic Immunity, LLC’s corporate website, SEC filings, investor presentations and featured press releases, both from Genetic Immunity, LLC and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- Genetic Immunity, LLC - Brief Genetic Immunity, LLC overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Genetic Immunity, LLC human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Genetic Immunity, LLC with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Genetic Immunity, LLC’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Genetic Immunity, LLC’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Genetic Immunity, LLC in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Genetic Immunity, LLC’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Genetic Immunity, LLC.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Genetic Immunity, LLC and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Genetic Immunity, LLC Snapshot 4
Genetic Immunity, LLC Overview 4
Key Information 4
Key Facts 4
Genetic Immunity, LLC - Research and Development Overview 5
Key Therapeutic Areas 5
Genetic Immunity, LLC - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Genetic Immunity, LLC - Pipeline Products Glance 9
Genetic Immunity, LLC-Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
Genetic Immunity, LLC - Drug Profiles 10
ChlamyDerm Vaccine 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
Genetic Immunity, LLC - Pipeline Analysis 11
Genetic Immunity, LLC - Pipeline Products by Therapeutic Class 11
Genetic Immunity, LLC - Pipeline Products By Target 12
Genetic Immunity, LLC - Pipeline Products by Route of Administration 13
Genetic Immunity, LLC - Pipeline Products by Molecule Type 14
Genetic Immunity, LLC - Recent Pipeline Updates 15
Genetic Immunity, LLC - Locations And Subsidiaries 16
Head Office 16
Other Locations and Subsidiaries 16
Recent Developments 17
July 19, 2010: Immunacia's Genetic Immunity Reports Phase II Data On DermaVir For HIV/AIDS At XVIII International AIDS Conference 17
April 16, 2009: Second Phase II clinical trial commences in Italy on Firms 's lead product candidate DermaVir Patch HIV vaccine 17
June 11, 2009: Firms completes patient enrollment in Phase II trial of DermaVir Patch HIV immunotherapeutic nanomedicine lead product candidate 18
April 11, 2011: Power of the Dream Ventures Announces Genetic Immunity's Phase II Trial Results for DermaVir HIV therapeutic Vaccine 19
July 09, 2010: Immunacia's Genetic Immunity Presents DermaVir At International Conference On Nanosciences and Nanotechnologies 19
Financial Deals Landscape 21
Genetic Immunity, LLC, Deals Summary 21
Genetic Immunity, LLC, Pharmaceuticals and Healthcare, Deal Details 22
Venture Financing 22
Genetic Immunity Secures US$ 2 Mln In Bridge Financing 22
Partnerships 23
Power Of The Dream Ventures Enters Into Co-development Agreement With Genetic Immunity 23
Licensing Agreements 24
Genetic Immunity Enters Into Licensing Agreement With Aldevron 24
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 27
Contact Us 27
Disclaimer 27

List of Tables

Genetic Immunity, LLC - Pipeline by Therapy Area and Indication, H2 2011 6
Genetic Immunity, LLC - Pipeline by Stage of Development, H2 2011 7
Genetic Immunity, LLC - Monotherapy Products in Pipeline, H2 2011 8
Genetic Immunity, LLC - Pre-Clinical, H2 2011 9
Genetic Immunity, LLC - Pipeline By Therapeutic Class, H2 2011 11
Genetic Immunity, LLC - Pipeline By Target, H2 2011 12
Genetic Immunity, LLC - Pipeline By Route of Administration, H2 2011 13
Genetic Immunity, LLC - Pipeline By Molecule Type, H2 2011 14
Genetic Immunity, LLC - Recent Pipeline Updates, H2 2011 15
Genetic Immunity, LLC, Other Locations 16
Genetic Immunity, LLC, Deals Summary 21
Genetic Immunity Secures US$ 2 Mln In Bridge Financing 22
Power Of The Dream Ventures Enters Into Co-development Agreement With Genetic Immunity 23
Genetic Immunity Enters Into Licensing Agreement With Aldevron 24

List of Figures

Genetic Immunity, LLC - Pipeline by Therapy Area and Indication, H2 2011 6
Genetic Immunity, LLC - Pipeline by Stage of Development, H2 2011 7
Genetic Immunity, LLC - Monotherapy Products in Pipeline, H2 2011 8

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

AmpliPhi Biosciences Corporation (formerly Targeted Genetics Corporation) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

AmpliPhi Biosciences Corporation (formerly Targeted Genetics Corporation) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • September 2014
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

Rosetta Genomics, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Rosetta Genomics, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • September 2014
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

Myriad Genetics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Myriad Genetics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • September 2014
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.